Given the in vitro findings and the prolonged survival in mice treated with a combination of carlumab and etoposide, the inhibition of CCL2 by carlumab was hypothesized to suppress the recruitment of monocytes and neuroblastoma cells to tumor sites while etoposide would exert its cytotoxic effect on residual tumor cells. The gene discussed is CCL2; the disease is neoplasm.